Dutch Adhesion Group - Thursday June 15

New horizons in prevention and treatment of adhesions

Adhesions continue to be a prominent cause of complications for all surgical specialities that frequently operate in the abdomen. In this symposium we will take an inspiring look into new developments in diagnosis, prevention and treatment of adhesions. The Dutch Adhesion Group will award a prize for the best free abstract related to adhesions, submittes to ESSR 2017.

Main topics:

Overview and state-of-the-art of adhesions and surgery Non-invasive diagnosis of adhesions Innovative prevention of adhesions Best abstracts and DAG award

Video's:

Non-invasive diagnosis of adhesions Elective adhesiolysis, operative technique Laparoscopic adhesiolysis for small bowel obstruction

www.adhesiepreventie.nl

Friday, June 16

eurzaal			
	Symposium One day on new strategies in the treatment of colo-rectal liver metastases		
	08.00-09.00	Registration, coffee and tea.	
	09.00-09.05	Welcome	T. van Gulik
	09.05-10.45	Chair: B. Nordlinger, T. van Gulik	

09.05-09.30 Liver resection for CRLM – The	gold standard M. Rees
09:30-09.55 Unresectable CRLM – How is it	_
09.55-10.20 Strategies to increase resectable	_
(ALPPS, PVE, RFA)	, , , , , , , , , , , , , , , , , , , ,
10.20-10.45 Laparoscopic liver resection for	CRLM M. Besselink
– Where are the limits?	
10.45-11.15 Coffee-break	
11.00-12.55 Chair: T. Ruers, M. Besselink	
11.15-11.40 The margin issue in resected CF	RLM P. Tanis
11.40-12.05 Concomitant resection of extra	-hepatic disease R. Adam
12.05-12.30 Systemic therapy – Strategies to	convert unresectable C. Punt
into resectable disease	
12.30-12.55 Peri-operative chemotherapy –	what to do now B. Nordlinger
12.30-12.55 Peri-operative chemotherapy –	what to do now B. Nordlinger
12.30-12.55 Peri-operative chemotherapy – 12.55-13.45 Lunch	what to do now B. Nordlinger
	what to do now B. Nordlinger
	what to do now B. Nordlinger
12.55-13.45 Lunch	
12.55-13.45 Lunch 13.45-15.25 Chair: D. Manas, P. Tanis	ored approach Y. Chun
12.55-13.45 Lunch 13.45-15.25 13.45-14.10 Chair: D. Manas, P. Tanis Ras mutations – the key to tailo	ored approach Y. Chun
12.55-13.45 Lunch 13.45-15.25 Chair: D. Manas, P. Tanis 13.45-14.10 Ras mutations – the key to tailed 14.10-14.35 Heat ablative therapies – When	ored approach Y. Chun e are we standing T. Ruers
12.55-13.45 Lunch 13.45-15.25 Chair: D. Manas, P. Tanis 13.45-14.10 Ras mutations – the key to tail of the standard of the sta	ored approach Y. Chun e are we standing T. Ruers M. Meijerink
12.55-13.45 Lunch 13.45-15.25 13.45-14.10 14.10-14.35 14.35-15.00 Chair: D. Manas, P. Tanis Ras mutations – the key to tailo Heat ablative therapies – When Nanoknife treatment of CRLM - The new kid on the block	ored approach Y. Chun e are we standing T. Ruers M. Meijerink
12.55-13.45 Lunch 13.45-15.25 Chair: D. Manas, P. Tanis Ras mutations – the key to tail 14.10-14.35 Heat ablative therapies – Wher 14.35-15.00 Nanoknife treatment of CRLM - The new kid on the block 15.00-15.25 Stereotactic body radiation the	ored approach Y. Chun e are we standing T. Ruers M. Meijerink
12.55-13.45 Lunch 13.45-15.25 Chair: D. Manas, P. Tanis Ras mutations – the key to tail 14.10-14.35 Heat ablative therapies – Wher 14.35-15.00 Nanoknife treatment of CRLM - The new kid on the block 15.00-15.25 Stereotactic body radiation the	ored approach Y. Chun e are we standing T. Ruers M. Meijerink
12.55-13.45 Lunch 13.45-15.25 13.45-14.10 14.10-14.35 14.35-15.00 Nanoknife treatment of CRLM - The new kid on the block 15.00-15.25 Lunch Chair: D. Manas, P. Tanis Ras mutations – the key to tailo Heat ablative therapies – Wher	ored approach Y. Chun e are we standing T. Ruers M. Meijerink
12.55-13.45 Lunch 13.45-15.25 13.45-14.10 14.10-14.35 14.35-15.00 Nanoknife treatment of CRLM - The new kid on the block 15.00-15.25 Lunch Chair: D. Manas, P. Tanis Ras mutations – the key to tailo Heat ablative therapies – Wher	ored approach e are we standing T. Ruers M. Meijerink rapy G. Westerveld

16.20-16.45 16.56-17.10 17.10-17.25	SIRT for CRLM SIRT and ALPPS SIRT for induction of parenchymal liver hypertrophy	D. Manas M. Schoen B. Garlipp
17.25	Closure	
17.30-18.30	Cocktails	

Saturday, June 17

The diabetic foot disease: Non-conventional diagnostic methods for distal ischemia and secondary prevention

Foot ulcers in diabetes form the complication most feared, leading to a major amputation in 15%. About 50% show signs of peripheral arterial insufficiency.

Although according to several reports, amputation can be prevented in a multidisciplinary setting in 50-85%, we are still confronted with an insufficient outcome regarding the amputation rate. One of the reasons is the high recurrence rate within one year, due to insufficient secondary prevention. Also, limited non-invasive vascular diagnostic methods to predict wound healing play an important role.

This symposium highlights several non-conventional diagnostic methods for early signs of recurrent ulcers and for quantification of the blood flow in the foot.